title: Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT).
abstract: To assess the prognostic relevance of activating mutations of FLT3 gene on outcome of allogeneic transplantations in AML patients, we performed an analysis of all patients with FLT3 mutations registered in the Czech Acute Leukemia Clinical Register (ALERT) from 2003 till the end of 2005. Within the mentioned period 170 patients with AML of median age 56 years (23-77) were investigated for FLT3 mutation, within them 36 cases (21%) with FLT3 mutations (32 FLT3 ITD and 4 FLT3 D835) were found. Out of FLT3 ITD positive patients 13 had allogeneic transplantation, 20 patients with mutations of FLT3 were treated with chemotherapy without transplantation. Results of the treatment of these patients were compared with the results of the group of patients without FLT3 mutation, which was according to other characteristics identical with the group of patients with FLT3 mutations (n=134). Median overall survival (OS) was significantly shorter for patients with FLT3 ITD (34.8 weeks) than for those without FLT3 mutations (67.7 weeks; P=0.028). Median OS of patients with FLT3 ITD who had allogeneic transplantation was 42.5 weeks; median OS of patients with FLT3 ITD treated only with chemotherapy was 29.6 weeks (P=0.362). After allogeneic transplantation, median OS of FLT3 mutations negative patients was similar to FLT3 ITD positive patients (46.7 versus 42.5 weeks; P=0.443). Our results suggest that at present there is no strong evidence that FLT3 status alone should influence the decision to proceed to allogeneic transplantation in AML patients. Decision to proceed to alogeneic transplantation should not be based on the FLT3 status only, but it should also consider other prognostic factors.
authors.affiliation: Department of Internal Medicine-Hematooncology, Masaryk University Hospital Brno, Czech Republic. mdoubek@fnbrno.cz
authors.forename: M
authors.initials: M
authors.lastname: Doubek
authors.forename: J
authors.initials: J
authors.lastname: Muzík
authors.forename: T
authors.initials: T
authors.lastname: Szotkowski
authors.forename: V
authors.initials: V
authors.lastname: Koza
authors.forename: P
authors.initials: P
authors.lastname: Cetkovský
authors.forename: T
authors.initials: T
authors.lastname: Kozák
authors.forename: P
authors.initials: P
authors.lastname: Zák
authors.forename: J
authors.initials: J
authors.lastname: Voglová
authors.forename: S
authors.initials: S
authors.lastname: Struncová
authors.forename: L
authors.initials: L
authors.lastname: Dusek
authors.forename: K
authors.initials: K
authors.lastname: Indrák
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018153:Czech Republic; D020440:Gene Duplication; D006801:Humans; D053208:Kaplan-Meier Estimate; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000235:genetics* / Q000601:surgery*; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D012042:Registries / Q000706:statistics & numerical data; D020080:Tandem Repeat Sequences; D013997:Time Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3